NZ777930A - Multivalent and multispecific dr5-binding fusion proteins - Google Patents

Multivalent and multispecific dr5-binding fusion proteins

Info

Publication number
NZ777930A
NZ777930A NZ777930A NZ77793016A NZ777930A NZ 777930 A NZ777930 A NZ 777930A NZ 777930 A NZ777930 A NZ 777930A NZ 77793016 A NZ77793016 A NZ 77793016A NZ 777930 A NZ777930 A NZ 777930A
Authority
NZ
New Zealand
Prior art keywords
multivalent
multispecific
fusion proteins
binding fusion
dr5bd
Prior art date
Application number
NZ777930A
Other languages
English (en)
Inventor
John Timmer
Kyle Jones
Amir Razai
Abrahim Hussain
Quinn Deveraux
Katelyn Willis
Brendan Eckelman
Original Assignee
Inhibrx Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Biosciences Inc filed Critical Inhibrx Biosciences Inc
Priority claimed from NZ738850A external-priority patent/NZ738850B2/en
Publication of NZ777930A publication Critical patent/NZ777930A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001138—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NZ777930A 2015-07-16 2016-07-18 Multivalent and multispecific dr5-binding fusion proteins NZ777930A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562193309P 2015-07-16 2015-07-16
NZ738850A NZ738850B2 (en) 2016-07-18 Multivalent and multispecific dr5-binding fusion proteins

Publications (1)

Publication Number Publication Date
NZ777930A true NZ777930A (en) 2025-05-02

Family

ID=57757772

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ777930A NZ777930A (en) 2015-07-16 2016-07-18 Multivalent and multispecific dr5-binding fusion proteins

Country Status (25)

Country Link
US (4) US10308720B2 (enExample)
EP (2) EP3322734B1 (enExample)
JP (4) JP6807606B2 (enExample)
KR (2) KR102760380B1 (enExample)
CN (2) CN107922491B (enExample)
AU (3) AU2016291701B2 (enExample)
CA (2) CA3288875A1 (enExample)
CY (1) CY1123615T1 (enExample)
DK (1) DK3322734T3 (enExample)
ES (1) ES2833773T3 (enExample)
HR (1) HRP20201785T1 (enExample)
HU (1) HUE051896T2 (enExample)
IL (4) IL328769A (enExample)
LT (1) LT3322734T (enExample)
MX (2) MX2018000523A (enExample)
NZ (1) NZ777930A (enExample)
PL (1) PL3322734T3 (enExample)
PT (1) PT3322734T (enExample)
RS (1) RS61062B1 (enExample)
RU (2) RU2021111382A (enExample)
SG (1) SG10201912410TA (enExample)
SI (1) SI3322734T1 (enExample)
SM (1) SMT202100066T1 (enExample)
WO (1) WO2017011837A2 (enExample)
ZA (1) ZA201800238B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY200973A (en) 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
JP2021508478A (ja) * 2017-12-28 2021-03-11 ユリウス・マクシミリアンス−ウニヴェルジテート・ヴュルツブルクＪｕｌｉｕｓ Ｍａｘｉｍｉｌｉａｎｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｗｕｅｒｚｂｕｒｇ ＦｃγＲ非依存性アゴニスト活性がある腫瘍壊死因子（ＴＮＦ）受容体スーパーファミリー（ＴＮＦＲＳＦ）受容体活性化抗体融合タンパク質（ＦｃγＲ非依存性アゴニスト活性があるＴＮＦＲＳＦ受容体活性化抗体融合タンパク質；ＴＲＡＡＦＦＩＡＡ）
CN110305210B (zh) * 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
TW202010757A (zh) 2018-04-11 2020-03-16 美商英伊布里克斯公司 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
WO2020047705A1 (zh) * 2018-09-03 2020-03-12 安菲尼生命科技有限公司 Dr5单域抗体及其用途
GB201903767D0 (en) * 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
AU2020358898B2 (en) * 2019-10-01 2025-10-16 Epsilogen Ltd Hybrid antibody
WO2022002038A1 (zh) * 2020-06-30 2022-01-06 和铂医药(上海)有限责任公司 免疫细胞衔接器多特异性结合蛋白及其制备和应用
EP4545569A3 (en) * 2020-06-30 2025-10-08 Harbour Biomed (Shanghai) Co., Ltd Binding protein having h2l2 and hcab structures
TWI818276B (zh) * 2020-06-30 2023-10-11 大陸商和鉑醫藥（上海）有限責任公司 Fab-HCAb結構的結合蛋白
CA3208641A1 (en) * 2021-02-19 2022-08-25 Ashraf AMANULLAH Formulations of dr5 binding polypeptides
WO2023196943A1 (en) * 2022-04-08 2023-10-12 Inhibrx, Inc. Dr5 agonist and plk1 inhibitor or cdk inhibitor combination therapy
EP4529455A1 (en) * 2022-05-23 2025-04-02 Inhibrx Biosciences, Inc. Dr5 agonist and iap antagonist combination therapy
CN117285644B (zh) * 2022-06-16 2026-05-15 清华大学 一种相变调节元件及其用途
CN120659804A (zh) 2022-09-28 2025-09-16 维连克治疗有限公司 多价蛋白质及筛选方法
KR20260032566A (ko) * 2023-06-29 2026-03-09 오디세이 테라퓨틱스, 인코포레이티드 항-trailr2 항원-결합 단백질 및 그의 용도

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE914504A1 (en) 1990-12-20 1992-07-01 Ixsys Optimization of binding proteins
US20020147140A1 (en) * 2000-01-31 2002-10-10 Rosen Craig A. Nucleic acids, proteins, and antibodies
KR20070010046A (ko) * 2004-04-06 2007-01-19 제넨테크, 인크. Ｄｒ5 항체 및 그의 용도
BRPI0518994A2 (pt) 2004-12-31 2008-12-02 Biogen Idec Inc anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
CA2598889A1 (en) 2005-02-24 2006-08-31 Cemines, Inc. Compositions and methods for classifying biological samples
CA2619725C (en) 2005-08-18 2016-06-07 Ramot At Tel Aviv University Ltd. Single chain antibodies against beta-amyloid peptide
EP1966242A1 (en) 2005-12-06 2008-09-10 Domantis Limited Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
DK1987178T3 (en) 2006-02-20 2015-04-20 Phylogica Ltd Process for the construction and screening of peptide structure libraries
JP2008133206A (ja) 2006-11-28 2008-06-12 Yokohama City Univ 緑膿菌に対して感染防御能を誘導できる医薬組成物
SG186017A1 (en) 2007-11-30 2012-12-28 Kalobios Pharmaceuticals Inc Antibodies to the pcrv antigen of pseudomonas aeruginosa
LT2285408T (lt) * 2008-06-05 2019-01-25 Ablynx N.V. Aminorūgščių sekos, nukreiptos prieš viruso apvalkalo baltymus, ir tokias sekas turintys polipeptidai, skirti virusinių ligų gydymui
US20110166076A1 (en) * 2008-09-10 2011-07-07 Bac Ip B.V. Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases
EP2408475B1 (en) 2009-03-18 2017-11-15 Wake Forest University Health Sciences Flagellin fusion proteins and use thereof to induce immune responses against pseudomonas aeruginosa
US20100281003A1 (en) 2009-04-02 2010-11-04 New York University System and uses for generating databases of protein secondary structures involved in inter-chain protein interactions
CN101717775B (zh) * 2009-11-13 2012-01-04 厦门大学 抗人死亡受体5的单链抗体基因
HRP20251657T1 (hr) 2009-12-14 2026-02-13 Ablynx N.V. Imunoglobulinska protutijela s jednostrukom varijabilnom domenom protiv ox40l, konstrukti i njihova terapijska upotreba
US9120855B2 (en) * 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
US8623369B2 (en) 2010-04-27 2014-01-07 National Research Council Of Canada Anti-ICAM-1 single domain antibody and uses thereof
US8877899B2 (en) 2010-09-27 2014-11-04 Morphosys Ag Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHL
CA2815888C (en) 2010-10-25 2020-06-30 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
CA2822684A1 (en) 2010-12-23 2012-06-28 Intercell Austria Ag Oprf/i agents and their use in hospitalized and other patients
MY167125A (en) 2011-08-17 2018-08-13 Glaxo Group Ltd Modified proteins and peptides
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
CN103906533A (zh) 2011-11-07 2014-07-02 米迪缪尼有限公司 多特异性和多价结合蛋白及其用途
CN104169304A (zh) 2011-12-20 2014-11-26 阿达拉塔合伙有限公司 作为pcsk9抑制剂的单域抗体
JP6415987B2 (ja) 2012-03-02 2018-10-31 アブリンクス エン．ヴェー． シュードモナス・エルギノーサのＰｃｒＶに結合する単一可変ドメイン抗体
WO2013167883A1 (en) 2012-05-07 2013-11-14 The University Court Of The University Of Aberdeen Single domain binding molecule
EP2684896A1 (en) * 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
WO2014043509A2 (en) 2012-09-13 2014-03-20 Novartis Ag Antigen binding molecule with terminal modifications
US20150284450A1 (en) 2012-11-06 2015-10-08 Medimmune, Llc Combination therapies using anti-pseudomonas psl and pcrv binding molecules
CN102924600B (zh) * 2012-11-14 2013-10-30 河南大学 死亡受体5激动性多价抗体及其在制备抗肿瘤药物中的应用
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
US9862777B2 (en) 2013-05-28 2018-01-09 Vib Vzw Single domain antibodies against SOD1 and their use in medicine
KR20160103007A (ko) * 2014-01-10 2016-08-31 각코호진 데이쿄 헤이세이 다이가쿠 재조합 편성 혐기성 그램 양성균

Also Published As

Publication number Publication date
IL328769A (en) 2026-07-01
EP3798232A1 (en) 2021-03-31
MX2018000523A (es) 2018-04-13
NZ738850A (en) 2024-11-29
IL256772A (en) 2018-03-29
HK1254433A1 (en) 2019-07-19
RU2018102803A (ru) 2019-08-19
EP3322734A2 (en) 2018-05-23
HUE051896T2 (hu) 2021-03-29
CY1123615T1 (el) 2022-03-24
JP2023022214A (ja) 2023-02-14
KR102760380B1 (ko) 2025-01-31
PT3322734T (pt) 2020-11-30
KR20250017305A (ko) 2025-02-04
AU2022291498A1 (en) 2023-02-02
SI3322734T1 (sl) 2021-02-26
RU2021111382A (ru) 2021-05-21
EP3322734B1 (en) 2020-09-09
KR20180030518A (ko) 2018-03-23
MX2023002379A (es) 2023-03-21
RU2748620C2 (ru) 2021-05-28
JP2021046414A (ja) 2021-03-25
ZA201800238B (en) 2021-07-28
CN107922491A (zh) 2018-04-17
IL256772B (en) 2022-05-01
CA3288875A1 (en) 2026-03-02
WO2017011837A3 (en) 2017-03-02
CA2991634A1 (en) 2017-01-19
HRP20201785T1 (hr) 2021-01-22
IL292037A (en) 2022-06-01
JP2018522888A (ja) 2018-08-16
AU2016291701A1 (en) 2018-01-25
US20190309083A1 (en) 2019-10-10
US20240376220A1 (en) 2024-11-14
ES2833773T3 (es) 2021-06-15
IL307994A (en) 2023-12-01
US20220064318A1 (en) 2022-03-03
CN114106178A (zh) 2022-03-01
JP6807606B2 (ja) 2021-01-06
CN107922491B (zh) 2021-09-28
SG10201912410TA (en) 2020-02-27
JP7244938B2 (ja) 2023-03-23
EP3322734A4 (en) 2019-04-17
CA2991634C (en) 2026-03-17
US11976126B2 (en) 2024-05-07
US11117973B2 (en) 2021-09-14
WO2017011837A2 (en) 2017-01-19
US20170015753A1 (en) 2017-01-19
RU2018102803A3 (enExample) 2019-12-27
RS61062B1 (sr) 2020-12-31
PL3322734T3 (pl) 2021-05-04
DK3322734T3 (da) 2020-10-26
AU2016291701B2 (en) 2022-09-29
LT3322734T (lt) 2021-02-10
US10308720B2 (en) 2019-06-04
SMT202100066T1 (it) 2021-03-15
JP2025084923A (ja) 2025-06-03
BR112018000584A2 (pt) 2018-09-11
AU2026200317A1 (en) 2026-02-05

Similar Documents

Publication Publication Date Title
MX2023007045A (es) Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) y metodos de uso de los mismos.
PH12018502400A1 (en) Anti-tim-3 antibodies and methods of use thereof
PH12017500819A1 (en) Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production
EP3152238A4 (en) Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
MX2023000818A (es) Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos.
IL264248A (en) Bispecific binding proteins, antibody-like, binding specifically to CD3 and CD123
EP4249515A3 (en) Humanized or chimeric cd3 antibodies
IL250622A0 (en) Prepared sirp-alpha fusion proteins and pharmaceutical preparations containing them
PH12016501212B1 (en) Human anti-il-33 neutralizing monoclonal antibody
MX2018000948A (es) Proteinas de fusion que se unen a gitir multivalentes y multiespecificas.
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
IL272103A (en) Antigen-binding proteins binding to 5T4 and 4-1BB, compositions and methods
EP3502143A4 (en) BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN
AR101829A1 (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1
MX2016016883A (es) Anticuerpo anti-axl.
PL3322734T3 (pl) Wielowartościowe i wielospecyficzne białka fuzyjne wiążące się z DR5
MX2024000004A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
PH12017500699A1 (en) Antibodies that bind to ccr6 and their uses
MX392543B (es) Método para purificación de proteína.
EP3242895A4 (en) A novel anti-egfr monoclonal antibody, method of making, and use thereof
MX2018011244A (es) Anticuerpos monoclonales neutralizantes para il-25 y usos de estos.
ZA201806767B (en) Recombinant intravenous immunoglobulin (rivig) compositions and methods for their production and use
PT3257524T (pt) Preparação de solução estabilizada de proteína de fusão de anticorpo glp-1r farmacêutica
BR112017003138A2 (pt) anticorpos anti-hepatite c e seus fragmentos de ligação ao antígeno
HK1248256A1 (zh) L型电压门控通道抗体及其相关方法

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: INHIBRX BIOSCIENCES, INC., US

Effective date: 20240704